Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Chinese PLA General Hospital Hainan Branch

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03602638

Enrollment

300

Registered

2018-07-27

Start date

2018-10-01

Completion date

2020-12-01

Last updated

2018-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1

Brief summary

This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.

Detailed description

This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.

Interventions

DRUGSitagliptin

Sitagliptin 100mg QD

DRUGAcarbose

Acarbose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients \> 18, \< 80 years old, with type 2 diabetes mellitus and coronary heart disease.

Exclusion criteria

* Allergy or hypersensitivity to any of the drug's components. Severe liver failure, moderate or severe kidney failure Malignant disease. Active infectious disease. Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame	Description
coronary calcification score	Changes from baseline in coronary calcification score at 18 months]	Changes in coronary calcification score in Patients with coronary heart disease complicated with Type 2 Diabetes was measure with Computed tomography angiography. To measure the changes in coronary calcification score at 18 months.

Contacts

Primary ContactLI BO, MD

22401919@qq.com+86089837330575

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026